Related Experiment Video

Updated: Aug 18, 2026

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
10:02

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Published on: March 12, 2020

Ropinirole in a child with attention-deficit hyperactivity disorder and restless legs syndrome

Eric Konofal1, Isabelle Arnulf, Michel Lecendreux

  • 1Service de Psychopathologie de l'Enfant et de l'Adolescent, Hôpital Robert Debré, Paris, France.

Pediatric Neurology
|May 4, 2005
PubMed

Insights

Ropinirole effectively treated a child with attention-deficit hyperactivity disorder (ADHD) and sleep issues. The dopamine agonist improved both ADHD symptoms and restless legs syndrome, offering a dual-action therapeutic benefit.

Area of Science:

  • Pediatric Neurology
  • Sleep Medicine
  • Pharmacology

Background:

  • Attention-deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children.
  • Methylphenidate immediate release is a first-line treatment for ADHD, but efficacy can be limited.
  • Sleep disturbances, including restless legs syndrome (RLS) and periodic limb movements of sleep (PLMS), can co-occur with ADHD.

Observation:

  • A 6-year-old male diagnosed with ADHD exhibited persistent symptoms despite treatment with methylphenidate.
  • The patient also experienced significant sleep disruption, suspected to be related to RLS/PLMS.
  • This case highlights the complex interplay between ADHD and sleep disorders in pediatric patients.

Findings:

  • Treatment with ropinirole, a dopamine agonist, was initiated to address the patient's sleep problems.
  • Ropinirole demonstrated significant efficacy in alleviating both the ADHD symptoms and the sleep disruption.
  • This suggests a potential dual benefit of ropinirole in managing comorbid ADHD and RLS/PLMS.

Implications:

  • Dopamine agonist therapy, specifically ropinirole, may be a viable treatment option for pediatric ADHD patients with comorbid sleep disorders.
  • Further research is warranted to explore the efficacy and safety of ropinirole in larger pediatric populations with ADHD and RLS/PLMS.
  • This case underscores the importance of evaluating and treating sleep disturbances in children with ADHD to optimize overall treatment outcomes.

More Related Videos

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy07:20

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

Published on: August 9, 2024

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Related Concept Videos

Restless Leg Syndrome and Night Terrors01:27

Restless Leg Syndrome and Night Terrors

Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...